Compounded

US Court Confirms FDA’s Decision to Ban Compounded Versions of Ozempic and Wegovy

by

A federal judge in New York has supported a U.S. Food and Drug Administration decision that prohibits the compounding of alternatives to the diabetes medication Ozempic and its weight-loss counterpart, Wegovy. The ruling comes amid soaring demand for these drugs, which have gained popularity for their effectiveness in managing weight. The case arose when a group of pharmacies sought to produce compounded versions of these medications, which are manufactured by Novo Nordisk. These compounded alternatives would allow pharmacists to create custom formulations for patients, yet the FDA argued that such practices may pose risks of … Read more

Lilly Seeks Court Action Against Compounded Copies of Its Popular Weight-Loss Medications

by

Indianapolis-based pharmaceutical giant Eli Lilly and Co. has requested to join a lawsuit targeting manufacturers of compounded versions of its popular weight-loss drugs. The company alleges that these compounded versions might pose safety risks and infringe on its intellectual property rights. This legal move comes as the U.S. weight-loss drug market experiences significant growth, driven by increasing awareness and consumer demand for effective obesity treatments. The lawsuit, originally filed by the U.S. Department of Justice, seeks to halt the production and distribution of unauthorized compounded versions of drugs similar to Lilly’s FDA-approved offerings, including Mounjaro … Read more

$34.9 Million Verdict in Trademark Dispute Shakes Up Pharmaceutical Industry: ImprimisRx Wins Case Over Compounded Eye Drops

by

San Diego, CA — A federal jury awarded $34.9 million to a pharmaceutical company following a heated four-day trial concerning trademark disputes over specialized post-surgical eyedrops. The verdict, handed down on Wednesday in a San Diego courtroom, addressed allegations of trademark infringement involving compounded ophthalmic medications. These medications are custom mixes specifically prepared to meet the unique needs of individual patients, particularly beneficial in eye care treatments. Carlsbad-based ImprimisRx LLC, which brought the lawsuit, claimed they pioneered the market with these unique formulations, each safeguarded under its own trademark. ImprimisRx LLC argued that competitor OSRX … Read more